a public good project by the
Synthesis
Company
of California

© 2026

Rubén Burgos‐Vargas | doi.page

0 works0 citations0 h-index

Rubén Burgos‐Vargas

Hospital General de México(MX)Universidad Nacional Autónoma de México(MX)

Publications by Year

Research Areas

Spondyloarthritis Studies and Treatments, Autoimmune and Inflammatory Disorders Research, Rheumatoid Arthritis Research and Therapies, Psoriasis: Treatment and Pathogenesis, Adolescent and Pediatric Healthcare

Most-Cited Works

→ Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis(2000)4,026 cited
→ The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis(2009)1,621 cited
→ Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis(2012)855 cited
→ Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial(2008)548 cited
→ The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo(2009)542 cited
→ Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group(2016)

514 cited

→ Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu(2010)413 cited

→ 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis(2011)409 cited

→ The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial(2010)373 cited

→ A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate(2004)372 cited